Europe (WHO region) vs Kazakhstan: Cases started on MDR-TB treatment
Europe (WHO region)
40,112
in 2024
Kazakhstan
4,641
in 2024
Europe (WHO region) rank
5th
Kazakhstan rank
7th
Cases started on MDR-TB treatment over time
- Europe (WHO region)
- Kazakhstan
How they compare
Europe (WHO region) currently reports 40,112 against 4,641 in Kazakhstan, a difference of 35,471.
That makes Europe (WHO region)'s figure about 8.6 times Kazakhstan's.
Across all 16 years both countries report, Europe (WHO region) has been ahead every year.
Europe (WHO region) ranks 5th and Kazakhstan ranks 7th of 11 groups.
Europe (WHO region) has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Europe (WHO region) | Kazakhstan | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 17,169 | 3,209 | 13,960 | Europe (WHO region) |
| 2010s | 45,082 | 6,228 | 38,855 | Europe (WHO region) |
| 2020s | 45,324 | 4,665 | 40,659 | Europe (WHO region) |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher cases started on mdr-tb treatment, Europe (WHO region) or Kazakhstan?
- Europe (WHO region), at 40,112 against 4,641 in Kazakhstan as of 2024.
- What is the difference in cases started on mdr-tb treatment between Europe (WHO region) and Kazakhstan?
- 35,471, with Europe (WHO region) ahead.
- How many years of comparable data are there for Europe (WHO region) and Kazakhstan?
- 16 years are reported by both, from 2009 to 2024.
- How do Europe (WHO region) and Kazakhstan rank globally for cases started on mdr-tb treatment?
- Europe (WHO region) ranks 5th and Kazakhstan ranks 7th of 11 groups.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Cases started on MDR-TB treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.